MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 465221 | Name: FD-105

Description:

WARNING: This product is for research use only, not for human or veterinary use.

FD-105 is an EGFR inhibitor.

Chemical Structure

FD-105
FD-105
CAS#unknown

Theoretical Analysis

MedKoo Cat#: 465221

Name: FD-105

CAS#: unknown

Chemical Formula: C14H11ClN4

Exact Mass: 270.0672

Molecular Weight: 270.72

Elemental Analysis: C, 62.11; H, 4.10; Cl, 13.09; N, 20.70

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
FD-105; FD105; FD 105;
IUPAC/Chemical Name
N4-(3-chlorophenyl)quinazoline-4,6-diamine
InChi Key
AWAYNEMCHILZCF-UHFFFAOYSA-N
InChi Code
InChI=1S/C14H11ClN4/c15-9-2-1-3-11(6-9)19-14-12-7-10(16)4-5-13(12)17-8-18-14/h1-8H,16H2,(H,17,18,19)
SMILES Code
ClC1=CC=CC(NC2=NC=NC3=CC=C(N)C=C32)=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 270.72 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Golabi N, Larroque AL, Peyrard L, Williams C, Jean-Claude BJ. Subcellular distribution and mechanism of action of AL906, a novel and potent EGFR inhibitor rationally designed to be green fluorescent. Invest New Drugs. 2021 Feb;39(1):240-250. doi: 10.1007/s10637-020-00958-7. Epub 2020 Jul 9. PMID: 32648119. 2: Chalifoux BD, Heilmann RK, Marshall HL, Schattenburg ML. Optical design of diffraction-limited x-ray telescopes. Appl Opt. 2020 Jun 1;59(16):4901-4914. doi: 10.1364/AO.392479. PMID: 32543486. 3: Al-Safadi S, Domarkas J, Han Y, Brahimi F, Jean-Claude BJ. Enhancement of the cytotoxic potential of the mixed EGFR and DNA-targeting 'combi-molecule' ZRBA1 against human solid tumour cells by a bis-quinazoline-based drug design approach. Anticancer Drugs. 2012 Jun;23(5):483-93. doi: 10.1097/CAD.0b013e328351c101. PMID: 22421369. 4: Golabi N, Rachid Z, Qiu Q, Huang Y, Jean-Claude BJ. In vitro and in vivo biodistribution of ZRS1, a stabilized type I N-acetoxymethyl carbamate- containing combi-molecule. Drug Metab Lett. 2011 Apr;5(2):141-9. doi: 10.2174/187231211795305212. PMID: 21457144. 5: Larroque-Lombard AL, Todorova M, Qiyu Q, Jean-Claude B. Synthesis and studies on three-compartment flavone-containing combi-molecules designed to target EGFR, DNA, and MEK. Chem Biol Drug Des. 2011 May;77(5):309-18. doi: 10.1111/j.1747-0285.2011.01098.x. Epub 2011 Mar 25. PMID: 21294849. 6: Todorova MI, Larroque AL, Dauphin-Pierre S, Fang YQ, Jean-Claude BJ. Subcellular distribution of a fluorescence-labeled combi-molecule designed to block epidermal growth factor receptor tyrosine kinase and damage DNA with a green fluorescent species. Mol Cancer Ther. 2010 Apr;9(4):869-82. doi: 10.1158/1535-7163.MCT-09-0673. Epub 2010 Mar 30. PMID: 20354119. 7: Qiu Q, Larroque AL, Gibbs B, Fang Y, Lakhrissi Y, Soucy JP, Mzengeza S, Rachid Z, Jean-Claude BJ. Molecular analysis of the in vivo metabolism and biodistribution of metabolically and non-metabolically activated combi-molecules of the triazene class. Drug Metab Lett. 2009 Jan;3(1):1-9. doi: 10.2174/187231209787176344. PMID: 19356110. 8: Merayo N, Rachid Z, Qiu Q, Brahimi F, Jean-Claude BJ. The combi-targeting concept: evidence for the formation of a novel inhibitor in vivo. Anticancer Drugs. 2006 Feb;17(2):165-71. doi: 10.1097/00001813-200602000-00007. PMID: 16428934. 9: Brahimi F, Rachid Z, McNamee JP, Alaoui-Jamali MA, Tari AM, Jean-Claude BJ. Mechanism of action of a novel "combi-triazene" engineered to possess a polar functional group on the alkylating moiety: evidence for enhancement of potency. Biochem Pharmacol. 2005 Aug 15;70(4):511-9. doi: 10.1016/j.bcp.2005.04.037. PMID: 15982640. 10: Brahimi F, Matheson SL, Dudouit F, McNamee JP, Tari AM, Jean-Claude BJ. Inhibition of epidermal growth factor receptor-mediated signaling by "Combi- triazene" BJ2000, a new probe for Combi-Targeting postulates. J Pharmacol Exp Ther. 2002 Oct;303(1):238-46. doi: 10.1124/jpet.102.039099. PMID: 12235257. 11: Provis JM, Sandercoe T, Hendrickson AE. Astrocytes and blood vessels define the foveal rim during primate retinal development. Invest Ophthalmol Vis Sci. 2000 Sep;41(10):2827-36. PMID: 10967034.

View History

NC-2100

NC-2100